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Summary and Implications 
The objective of the current study was to investigate the 
effects of different feeding rates achieving three targeted 
growth rates (No Growth, Low Growth, and High Growth) 
on adaptive immune responses of neonatal calves vaccinated 
with Mycobacterium bovis bacillus Calmette-Guerin (BCG) 
and ovalbumin (OVA) 3 wks after initiation of dietary 
treatments.  The daily growth rates for No-, Low-, and 
High-growth calves were different throughout the 
experimental period and averaged 0.11 ± 0.02 kg, 0.58 ± 
.02, and 1.16 ± 0.04 kg, respectively.  Adaptive immune 
responses generally were not affected by growth rate.  
Ovalbumin-specific IgG1 and IgG2 concentrations after 
vaccination were not affected by growth rate.  Interferon 
(IFN)-γ and nitric oxide (NO) secretion by PPD-stimulated 
mononuclear leukocytes (MNL) also were not affected by 
growth rate.  Antigen (i.e., PPD)-elicited delayed-type 
hypersensitivity in No-growth calves was greater than Low-
growth but similar to High-growth calves.  Viability of 
MNL, CD4+, CD8+, and γδTCR+ cells in stimulated and 
non-stimulated cultures from High-growth calves was 
substantially lower compared with No- and Low-growth 
calves.  These results suggest protein-energy malnutrition 
(PEM) in the absence of weight loss does not affect 
negatively adaptive immune responses of calves and that 
increasing growth rate or plane of nutrition above 
maintenance requirements does not benefit adaptive 
immune responses.  High rates of growth, however, may 
affect negatively immune cell viability, with potentially 
deleterious effects on the calf’s resistance to infectious 
disease.  
 
Introduction 
Neonatal animals are highly susceptible to bacterial and 
viral pathogens.  Traditional calf-rearing programs limit 
nutrient intake from milk or milk replacer during the first 
few weeks of life in order to promote dry feed (i.e., starter) 
intake and allow early weaning.  Recent reports of dramatic 
improvements in the growth performance and feed 
efficiency resulting from feeding greater amounts of milk 
replacer with higher protein concentrations has led to 
interest in intensified or accelerated feeding programs.  It is 
believed that intensified feeding programs increase the plane 
of nutrition to more “natural” levels and provide more 
“biologically appropriate” early growth.  Improving the 
plane of nutrition also may improve calf health and decrease 
morbidity and mortality. 
Protein-energy malnutrition is the major cause of 
immunodeficiency worldwide.  Protein-energy malnutrition 
manifests as acute (wasting) and chronic (stunting) forms, 
resulting in altered body composition and decreased linear 
growth, respectively.  Reports suggest that stunting and 
wasting PEM may depress cell-mediated 
immunocompetence and increase the risk of infection-
related mortality.  Most experiments to date have 
investigated effects of wasting-, not stunting-, PEM on 
immunity.  Substantial evidence supports negative effects of 
PEM on adaptive immune responses.  Alternatively, 
restricting dietary protein and energy affects positively 
immune function and longevity in rodents.   
We hypothesize that increasing plane of nutrition above 
maintenance requirements does not enhance adaptive 
immune responses in vaccinated neonatal calves.   
 
Materials and Methods 
Animals 
Twenty-four Holstein bull calves were acquired from a 
single Wisconsin dairy herd over a 2-wk period.  All calves 
were given 3.9 L each of colostrum within 6 h of birth.  
After birth, calves were transported to the National Animal 
Disease Center, ARS, USDA, Ames, IA, where they were 
housed individually in elevated pens in a temperature-
controlled (64°C) barn.   
 
Dietary Treatments 
Treatments were designed to achieve three targeted 
daily rates of gain (No Growth = 0.0 kg, Low Growth = 
0.55 kg, or High Growth = 1.2 kg) in live weight over a  
7-wk period.  The NRC Nutrient Requirements of Dairy 
Cattle calf model computer program was used to estimate 
milk replacer intakes needed to achieve target growth rates.  
All calves were fed a 30% CP, 20% F all-milk protein milk 
replacer (Land O’ Lakes, Inc.) reconstituted to 14% dry 
matter.  Calves were weighed each Monday at midday, and 
diets were reformulated to allow for changes in live weight.  
No starter grain was offered, and water was offered ad 
libitum. 
   
Vaccination 
At wk 3 of the experiment, all calves were vaccinated 
subcutaneously in the right midcervical region with 107 cfu 
of M. bovis BCG.  At wk 3 and wk 5 of the experiment, 
adjuvanted OVA (4 mg OVA in incomplete Freund’s 
adjuvant) was administered to all calves subcutaneously in 
the left midcervical region.   
 
Blood Collection 
Peripheral blood (90 mL) was collected via jugular 
venipuncture at wk 0, 3 (time of primary sensitization), 5 
(time of OVA secondary vaccination), 6, and 7 of the 
experimental period.  Coagulated (no additive) blood 
samples also were collected once weekly during the 
experimental period for quantification of antigen-specific 
IgG concentrations.  
 
Recall Antigens   
Recall antigens used for in vivo and in vitro assays were 
crystallized ovalbumin (Grade V, Sigma) and M. bovis-
derived purified protein derivative (PPD; Pfizer, 
Kalamazoo, MI.).   
 
Assays 
OVA-specific IgG1 and IgG2 concentrations in serum 
samples collected weekly before and after vaccination were 
determined by a capture ELISA. 
Cells used in IFN-γ assays were from blood samples 
collected at wk 3, 5, and 7 of the experimental period.  
Wells were seeded with 4 × 105 cells in a total culture 
volume of 200 μL.  Cultures were either non-stimulated 
(medium alone) or stimulated with PPD (10 μg/mL) or 
OVA (10 μg/mL).  Cultures were incubated at 39°C in a 
humidified atmosphere of 5% CO2 for 72 h.  Supernatants 
were subsequently harvested from centrifuged plates and 
stored at -80°C.  The IFN-γ concentration (ng/mL) in 
culture supernatants was determined by using an IFN-γ 
capture ELISA. 
Cells used in NO assays were from blood samples 
collected at wk 3 (before vaccination), 5, and 7 of the 
experimental period.  Wells were seeded with 4 × 105 cells 
in a total culture volume of 200 μL.  Cultures were non-
stimulated (medium alone), stimulated with 10 μg/mL 
OVA, or with 10 μg/mL M. bovis PPD.  Plates were 
incubated at 39°C in a humidified atmosphere of 5% CO2 
for 48 h.  The amount of nitrite in culture supernatants was 
measured using the Griess reagent. 
In vivo sensitization to M. bovis BCG was evaluated by 
using the comparative cervical skin test following Bovine 
Tuberculosis Eradication Uniform Methods and Rules 
(Animal and Plant Health Inspection Service brochure #91-
45-011).  Skin-fold thickness was measured immediately 
before administration of PPD and 72 h later.   
 
 
 
Viability of MNL 
Viability of blood MNL in non-stimulated and OVA- 
and PPD-stimulated cultures was evaluated when calves had 
been on dietary treatments for 7 wk.  Cultures were non-
stimulated (media only) or stimulated with OVA (10 
μg/mL) or PPD (10 μg/mL) and incubated for 3 d at 39°C in 
a humidified atmosphere with 5% CO2.  Cells were labeled 
with one of three phenotype makers (CD4, CD8, or γδTCR) 
and with 7-amino actinomycin D (7-AAD).  Cells were 
analyzed via flow cytometry.  Cells without 7-AAD labeling 
were considered viable, whereas apoptotic and dead cells 
showed low and high 7-AAD staining, respectively. 
 
Results and Discussion 
Growth Performance 
This study describes, for the first time, the effects of 
feeding at different rates to achieve targeted daily growth 
rates on adaptive immune responses in neonates.  Mean 
body weights of calves from the three treatment groups were 
different (P < 0.05) by wk 1 (Figure 1).  The daily growth 
rates for No-, Low-, and High-Growth calves were different 
(P < 0.0001) throughout the experimental period and 
averaged 0.11 ± 0.02 kg, 0.58 ± .02, and 1.16 ± 0.04 kg, 
respectively.   
 
Antibody Response to Ovalbumin Vaccination 
Serum OVA-specific IgG1 and IgG2 increased (P < 
0.05) following vaccination (Figures 2a and 2b, 
respectively).  Growth rate did not affect (P > 0.5) OVA-
specific IgG1 or IgG2 concentration in serum across time, 
suggesting calves fed a diet resulting in no growth have 
normal in vivo antibody responses.  Two wk following 
primary vaccination (wk 5), concentration of OVA-specific 
IgG2 was higher (P < 0.05) in High-Growth than in Low-
Growth calves.  Concentration of OVA-specific IgG2 was 
similar (P > 0.05) in High- and No-Growth calves.   
 
Secretion of IFN-γ and NO by Blood MNL in Response to 
Antigen  
We have shown previously that M. bovis BCG-
vaccinated calves exhibit strong cell-mediated immune 
(CMI) responses to PPD.  In the present study, a BCG 
sensitization and challenge model was used to evaluate 
effects of growth rate on adaptive CMI responses of milk 
replacer-fed calves.  By using this model, we evaluated IFN-
γ and NO production in antigen-stimulated blood MNL 
cultures, which are functions intimately associated with 
CMI.  Effects of growth rate on secretion of IFN-γ in OVA- 
and PPD-stimulated cultures are shown in Figure 3.  
Secretion of IFN-γ by OVA-stimulated blood MNL from 
No- and High-Growth calves increased (P < 0.01) with time 
following vaccination, whereas IFN-γ responses to OVA 
stimulation by MNL from Low-Growth calves did not 
change (P > 0.05) with time (Figure 3a).  Growth rate did 
not affect (P > 0.05) secretion of IFN-γ by PPD-stimulated 
blood MNL from calves (Figure 3b).  Secretion of IFN-γ by 
PPD-stimulated MNL did increase (P < 0.01) with time 
following vaccination. 
Conclusions 
The effects of growth rate on adaptive immune 
responses to OVA and M. bovis BCG vaccination in calves 
were minimal, suggesting PEM in the absence of weight 
loss does not affect adaptive immune responses of the 
neonate.  Weight loss may be a requirement to achieve 
PEM-induced immunodeficiency.  High growth rates, 
however, decreased immune cell viability, having 
potentially deleterious effects on disease resistance. Further 
investigation is required to determine if high rates of growth 
induce metabolic/oxidative stress on cells of the immune 
system. 
Effects of growth rate on NO production are shown in 
Figure 4.  Growth rate did not affect (P > 0.05) NO 
production by PPD-stimulated MNL.  Production of NO by 
PPD-stimulated blood MNL from High-, Low-, and NO-
Growth calves increased (P < 0.05) with time following 
vaccination.   
 
Cutaneous delayed-type hypersensitivity (DTH)  
Responses to intradermal administration of M. bovis 
PPD 5 wk following vaccination are shown in Figure 5.  
Change in skin fold thickness was greater (P < 0.05) in No-
Growth calves compared with Low-Growth but not High-
Growth calves, suggesting that calves fed a diet resulting in 
no growth have normal DTH reactions that are indicative of 
competent in vivo CMI responses.   
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Blood MNL viability in culture 
Growth rate affected the viability of blood MNL in 
non-stimulated and antigen-stimulated cultures (Figure 6).  
Percentages of viable MNL, CD4+, CD8+, and γδTCR+ cells 
in non-stimulated (Figure 6a) and PPD-stimulated cultures 
(Figure 6b) established from cells isolated from High-
Growth calves were lower (P < 0.01) compared with No- 
and Low-Growth calves.   
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Figure 1.  Growth performance of calves fed milk replacer at three rates of intake to achieve 
three targeted daily rates of gain. 
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Figure 2.  Relative amounts of ovalbumin-specific IgG1 (panel a) and IgG2 (panel b) in serum from calves fed 
milk replacer at three rates of intake to achieve no (n = 8), low (n = 8), or high (n = 8) growth rates.   
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Figure 3.  In vitro interferon (IFN)-γ secretion by blood mononuclear cells (MNL) from calves fed 
milk replacer at three rates of intake to achieve no (n = 8), low (n = 8), or high (n = 8) growth rates. 
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Figure 4.  In vitro nitric oxide (NO) secretion by blood mononuclear cells (MNL) from calves fed milk 
replacer at three rates of intake to achieve no (n = 8), low (n = 8), or high (n = 8) growth rates. 
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Figure 5.  In vivo delayed-type hypersensitivity reactions of calves fed milk replacer at 
three rates of intake to achieve no (n = 8), low (n = 8), or high (n = 8) growth rates. 
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Figure 6.  Viability of blood mononuclear cells (MNL) from calves fed milk replacer at three rates of 
intake to achieve no (n = 4), low (n = 4), or high (n = 4) growth rates for 7 wk. 
 
 
 
